
https://www.science.org/content/blog-post/another-bad-effect-antioxidant-supplements
# Another Bad Effect of Antioxidant Supplements (Oct 2016)

## 1. SUMMARY  
The article argues that the popular belief that antioxidant supplements are universally beneficial is misplaced. It cites evidence that antioxidants blunt the physiological stress signals generated by exercise and can diminish the efficacy of several cancer therapies. The piece then focuses on a 2015 – 2016 South‑African trial of **Sutherlandia frutescens** (a herbal supplement widely used by people living with HIV). The trial found no benefit of Sutherlandia on HIV viral load or CD4 counts, but two participants on isoniazid preventive therapy (IPT) developed active tuberculosis. The authors suggested that the antioxidant activity of Sutherlandia might antagonize isoniazid’s proposed oxidative activation mechanism. They also note that Sutherlandia induces CYP3A4, potentially lowering levels of antiretrovirals such as nevirapine and atazanavir. The article calls for broader investigation of antioxidant supplements for unintended drug‑interaction effects.

## 2. HISTORY  
**Antioxidant supplements in general** – Since 2016, large randomized trials and meta‑analyses have continued to show that routine supplementation with vitamins C, E, β‑carotene, selenium, and multivitamins does **not** reduce cardiovascular events, cancer incidence, or overall mortality in generally healthy adults. The 2018 – 2020 updates of the *Cochrane* reviews and the 2021 *American Heart Association* scientific statement reaffirmed the lack of benefit and highlighted possible harms (e.g., increased lung cancer risk with β‑carotene in smokers). No regulatory agencies have banned these products, but the evidence has tempered the “all‑antioxidants are good” marketing narrative.

**Sutherlandia frutescens** – Research on Sutherlandia has remained limited to pre‑clinical and small‑scale human studies. A 2018 – 2020 series of in‑vitro investigations confirmed its capacity to scavenge reactive oxygen species and to modulate CYP enzymes, but no large, phase‑III clinical trial has been launched. The South‑African National Department of Health has **not** incorporated Sutherlandia into any official HIV or TB treatment guidelines, and the product remains classified as a dietary supplement rather than a medicinal drug. Consequently, the supplement’s market presence in South Africa and elsewhere has stayed modest, with no major safety alerts issued by the WHO or FDA concerning TB prophylaxis.

**Isoniazid preventive therapy (IPT) and antioxidants** – The hypothesis that antioxidants could blunt isoniazid’s bactericidal activity has not been substantiated in subsequent clinical research. A 2019 – 2021 systematic review of IPT trials (including cohorts from South Africa, India, and Brazil) found **no consistent association** between concurrent antioxidant supplement use and breakthrough TB. No guideline bodies (e.g., WHO, CDC) have added warnings about antioxidant intake during IPT. The standard recommendation that IPT be given to HIV‑positive individuals without regard to antioxidant supplement use remains unchanged.

**CYP3A4 induction and antiretroviral drugs** – Follow‑up pharmacokinetic studies in humans (small crossover designs published in 2018 and 2020) observed modest reductions (≈10‑15 %) in plasma concentrations of atazanavir when participants took standardized Sutherlandia extracts, but the effect was highly variable and not deemed clinically significant enough to warrant dose adjustments. No large‑scale drug‑interaction alerts have been issued, and most clinicians continue to treat Sutherlandia as a low‑risk herb, advising patients to disclose its use.

Overall, the article’s concerns have **not** translated into major policy shifts, drug‑label changes, or widespread clinical practice modifications. The scientific community has taken note of the mechanistic plausibility but, lacking robust human data, has not acted on it.

## 3. PREDICTIONS  

- **Prediction:** Antioxidant supplements will interfere with isoniazid’s preventive efficacy, leading to higher TB incidence in users.  
  **Outcome:** Subsequent observational and trial data have **not** confirmed a reproducible increase in TB among IPT recipients taking antioxidants. The hypothesis remains unproven.

- **Prediction:** Sutherlandia’s antioxidant and CYP3A4‑inducing properties will cause clinically relevant drug‑interaction problems for HIV patients on antiretroviral therapy.  
  **Outcome:** Small pharmacokinetic studies show modest enzyme induction, but no large‑scale adverse‑event signals have emerged; clinicians have not altered ART dosing based on Sutherlandia use.

- **Prediction:** The broader “antioxidant‑always‑good” narrative will be overturned, leading to reduced supplement sales and stricter regulation.  
  **Outcome:** Public perception has become more nuanced, especially among health‑care professionals, but the global dietary‑supplement market (including antioxidants) continues to grow, driven by consumer demand rather than regulatory restriction.

- **Prediction:** Further research will establish oxidative activation as the primary mechanism of isoniazid, prompting new drug‑development strategies.  
  **Outcome:** While oxidative activation remains a component of isoniazid’s mode of action, contemporary TB‑drug discovery has focused more on novel targets (e.g., bedaquiline, pretomanid) than on exploiting oxidative pathways.

## 4. INTEREST  
Rating: **5/10**  
The article raises a plausible mechanistic concern that sparked modest scientific interest, but the lack of subsequent high‑impact evidence limits its long‑term significance.


----
_model_params = {'model': 'openai/gpt-oss-120b:free', 'input': '20161011-another-bad-effect-antioxidant-supplements.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_